AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Long Run with Luke Timmerman
Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery
May 20, 2024
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, discuss using synthetic biology and AI for drug discovery. They explore yeast as a platform, business representation challenges, and innovative approaches to developing antibodies. The podcast dives into how AI revolutionizes drug discovery and optimization, impacting human health through unique biological understanding.
01:00:44
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- A-Alpha Bio utilizes synthetic biology and AI for drug discovery focusing on protein-protein interactions.
- Their data-driven platform with AI integration revolutionizes drug development workflows.
Deep dives
A.A.L. Fabio's Innovative Approach to Protein-Protein Interactions
A.A.L. Fabio, a Seattle-based company, specializes in high-volume synthetic biology to analyze protein-protein interactions using machine learning. Their sin-bio and AI technologies help identify drug candidates with specific optimal characteristics, like high-affinity binding to particular epitopes. Collaborating with industry giants like Gilead Sciences, Amgen, and Bristol Myers-Squibb, they work on developing molecular glue therapies.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode